Nanobiotix S.A./€NANO

1D1W1MYTD1Y5YMAX

About Nanobiotix S.A.

Nanobiotix S.A. is a biotechnology company focusing on developing innovative nanomedicine solutions for cancer therapy. Its core business is centered around the development of NBTXR3, a radioenhancer designed to increase the efficacy of radiotherapy in cancer treatment. Founded in 2003, Nanobiotix is headquartered in Paris, France. Its strategic positioning lies in its proprietary nanotechnology platform, which aims to address unmet needs in oncology by potentially improving outcomes and safety for patients undergoing radiotherapy. The company operates primarily within the European and U.S. markets, with ongoing clinical trials to expand its therapeutic applications.
Ticker
€NANO
Sector
Health
Primary listing
PAR
Employees
100
Headquarters
Paris, France
Website
www.nanobiotix.com

Nanobiotix S.A. Metrics

BasicAdvanced
€1.5B
-
-€0.50
0.58
-

Bulls say / Bears say

Phase 2 CONVERGE data presented at ESTRO 2026 showed an investigator-reported overall response rate (ORR) of 85.7% and a complete response rate (CRR) of 57.1% in seven patients with unresectable stage III NSCLC—far exceeding the <5% CRR with standard of care—while no serious treatment-emergent adverse events were reported. (GlobeNewswire)
In May 2026, Nanobiotix completed a follow-on offering generating approximately €86.1 million in gross proceeds, bolstering its cash position and funding the accelerated development of its nanotherapeutic platforms. (GlobeNewswire)
The FDA accepted a protocol amendment for the global Phase 3 NANORAY-312 head and neck cancer study—eliminating an interim analysis and reducing event requirements—to expedite final analysis and potentially shorten the path to approval. (GlobeNewswire)
The May 2026 follow-on offering issued 2,218,467 new ordinary shares and 345,099 pre-funded warrants, significantly diluting existing shareholders’ stakes. (SEC.gov)
Efficacy signals from the Phase 2 CONVERGE safety lead-in are based on only seven patients, leaving uncertainty about consistency of these results in larger, randomized cohorts. (Tiger Brokers)
The company’s projection that its €42.1 million cash balance plus offering proceeds will fund operations into 2029 depends on management’s assumptions and carries the risk of unforeseen cash burn increases requiring further dilutive financings. (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 5 Sept 2026.

Funds containing Nanobiotix S.A.

AllUSDEURGBP
Funds
Fund name
Fund size
€NANO weighting
iShares Healthcare Innovation$HEAL
$1.4B0.12%
iShares Healthcare Innovation€2B78
€1.2B0.12%
iShares Healthcare Innovation£DRDR
£1B0.12%
iShares Ageing Population€AGED
€822M0.10%
Xtrackers MSCI Europe Small Cap€DX2J
€3.2B0.07%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.